Your browser doesn't support javascript.
loading
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Norden, Andrew D; Schiff, David; Ahluwalia, Manmeet S; Lesser, Glenn J; Nayak, Lakshmi; Lee, Eudocia Q; Rinne, Mikael L; Muzikansky, Alona; Dietrich, Jorg; Purow, Benjamin; Doherty, Lisa M; LaFrankie, Debra C; Pulverenti, Julee R; Rifenburg, Jennifer A; Ruland, Sandra F; Smith, Katrina H; Gaffey, Sarah C; McCluskey, Christine; Ligon, Keith L; Reardon, David A; Wen, Patrick Y.
Affiliation
  • Norden AD; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115, USA, anorden@partners.org.
J Neurooncol ; 121(2): 297-302, 2015 Jan.
Article in En | MEDLINE | ID: mdl-25338318
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glioma / Indoles / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurooncol Year: 2015 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glioma / Indoles / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurooncol Year: 2015 Document type: Article Country of publication: